Adaptive Multipath Key Reinforcement for Energy Harvesting Wireless Sensor Networks

AbstractEnergy Harvesting - Wireless Sensor Networks (EH-WSNs) constitute systems of networked sensing nodes that are capable of extracting energy from the environment and that use the harvested energy to operate in a sustainable state. Sustainability, seen as design goal, has a significant impact on the design of the security protocols for such networks, as the nodes have to adapt and optimize their behaviour according to the available energy. Traditional key management schemes do not take energy into account, making them not suitable for EH-WSNs. In this paper we propose a new multipath key reinforcement scheme specifically designed for EH-WSNs. The proposed scheme allows each node to take into consideration and adapt to the amount of energy available in the system. In particular, we present two approaches, one static and one fully dynamic, and we discuss some experimental results

Adaptive Security in ODMAC for Multihop Energy Harvesting Wireless Sensor Networks

Energy Harvesting Wireless Sensor Networks (EH-WSNs) represent an interesting new paradigm where individual nodes forming a network are powered by energy sources scavenged from the surrounding environment. This technique provides numerous advantages, but also new design challenges. Securing the communications under energy constraints represents one of these key challenges. The amount of energy available is theoretically infinite in the long run but highly variable over short periods of time, and managing it is a crucial aspect. In this paper we present an adaptive approach for security in multihop EH-WSNs which allows different nodes to dynamically choose the most appropriate energy-affecting parameters such as encryption algorithm and key size, providing in this way energy savings. In order to provide evidence of the approach's feasibility in a real-world network, we have designed and implemented it as extension of on-demand medium access control (ODMAC), a receiver-initiated (RI) MAC protocol specifically designed and developed to address the foundational energy-related needs of Energy Harvesting Wireless Sensor Networks

Brexpiprazole as a new approach of treatment in somatization disorder

© 2022 Published by Elsevier Ltd on behalf of International Society for the Study of Emerging Drugs. This is an open access article under the CC-BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)Introduction: Somatic symptom disorder (SSD) is a mental disorder that involves one or more physical symptoms (e.g. palpitations, dizziness, diarrhoea, limb weakness, pain, and pseudo neurological symptoms) accompanied by one or more thoughts, feelings, and/or behaviours related to the somatic symptom(s) resulting in significant distress and/or dysfunction lasting for more than 6 months. At now the SSD can be refractory to psychiatric intervention including antidepressants, antiepileptics, and antipsychotics as well as the effectiveness of many of these treatments is limited. The objective of this study was to report the effectiveness of a third-generation antipsychotic drug brexpiprazole for treatment of a case of SSD together with the serotonin selective reuptake inhibitor (SSRI) fluvoxamine. Methods: A single case study of a 59-year-old female with SSD was here performed. Findings: After 4 weeks of treatment brexpiprazole, together with lamotrigine and fluvoxamine, was here effective in decreasing both depressive and anxiety symptoms, normalising previous unusual thought contents and of related behaviours. The patient reported an overall good response and started to function again in important domains of life. No adverse events occurred. Conclusion: To our knowledge, this is the first case showing Brexpiprazole effective for the treatment of a case of SSD as add-on to other drugs.Peer reviewedFinal Published versio

Therapeutic Potentials of Ketamine and Esketamine in Obsessive–Compulsive Disorder (OCD), Substance Use Disorders (SUD) and Eating Disorders (ED): A Review of the Current Literature

The obsessive–compulsive spectrum refers to disorders drawn from several diagnostic categories that share core features related to obsessive–compulsive disorder (OCD), such as obsessive thoughts, compulsive behaviors and anxiety. Disorders that include these features can be grouped according to the focus of the symptoms, e.g., bodily preoccupation (i.e., eating disorders, ED) or impulse control (i.e., substance use disorders, SUD), and they exhibit intriguing similarities in phenomenology, etiology, pathophysiology, patient characteristics and clinical outcomes. The non-competitive N-methyl-D-aspartate receptor (NMDAr) antagonist ketamine has been indicated to produce remarkable results in patients with treatment-resistant depression, post-traumatic stress disorder and OCD in dozens of small studies accrued over the past decade, and it appears to be promising in the treatment of SUD and ED. However, despite many small studies, solid evidence for the benefits of its use in the treatment of OCD spectrum and addiction is still lacking. Thus, the aim of this perspective article is to examine the potential for ketamine and esketamine in treating OCD, ED and SUD, which all involve recurring and intrusive thoughts and generate associated compulsive behavior. A comprehensive and updated overview of the literature regarding the pharmacological mechanisms of action of both ketamine and esketamine, as well as their therapeutic advantages over current treatments, are provided in this paper. An electronic search was performed, including all papers published up to April 2021, using the following keywords (“ketamine” or “esketamine”) AND (“obsessive” OR “compulsive” OR “OCD” OR “SUD” OR “substance use disorder” OR “addiction” OR “craving” OR “eating” OR “anorexia”) NOT review NOT animal NOT “in vitro”, on the PubMed, Cochrane Library and Web of Science online databases. The review was conducted in accordance with preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines. The use and efficacy of ketamine in SUD, ED and OCD is supported by glutamatergic neurotransmission dysregulation, which plays an important role in these conditions. Ketamine’s use is increasing, and preliminary data are optimistic. Further studies are needed in order to better clarify the many unknowns related to the use of both ketamine and esketamine in SUD, ED and OCD, and to understand their long-term effectiveness.Peer reviewedFinal Published versio